Wells Fargo & Company Begins Coverage on Atyr PHARMA (NASDAQ:ATYR)

Wells Fargo & Company started coverage on shares of Atyr PHARMA (NASDAQ:ATYR - Free Report) in a report issued on Friday morning, MarketBeat Ratings reports. The brokerage issued an overweight rating and a $17.00 target price on the stock.

A number of other equities analysts have also commented on ATYR. Royal Bank of Canada reissued an outperform rating and issued a $16.00 price target on shares of Atyr PHARMA in a report on Wednesday, August 14th. Jefferies Financial Group assumed coverage on shares of Atyr PHARMA in a research note on Thursday, September 5th. They issued a buy rating and a $9.00 price objective for the company. Finally, HC Wainwright reaffirmed a buy rating and issued a $35.00 price objective on shares of Atyr PHARMA in a research note on Thursday, August 15th.

Atyr PHARMA Trading Up 7.5 %

Shares of NASDAQ:ATYR traded up $0.13 during trading on Friday, reaching $1.87. The company had a trading volume of 2,873,582 shares, compared to its average volume of 465,097. The company has a fifty day moving average price of $1.85. The stock has a market cap of $129.05 million, a PE ratio of -2.08 and a beta of 1.21. Atyr PHARMA has a 12 month low of $1.08 and a 12 month high of $2.50. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.63 and a quick ratio of 7.63.

Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($0.24) by $0.01. As a group, equities research analysts predict that Atyr PHARMA will post -0.91 earnings per share for the current year.

Insider Activity

In other news, Director Paul Schimmel purchased 41,052 shares of the company's stock in a transaction on Monday, July 22nd. The stock was acquired at an average price of $1.74 per share, with a total value of $71,430.48. Following the transaction, the director now directly owns 354,075 shares of the company's stock, valued at approximately $616,090.50. This represents a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 3.70% of the stock is owned by corporate insiders.

Atyr PHARMA Company Profile

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.